The recent identification of germline and somatic mutations in BAP1 as well as in multiple members of the ASXL (additional sex combs-like) family of genes has highlighted the role of these proteins in a diverse array of biological functions. A diverse number of possible functions have previously been ascribed to ASXL1 in non-hematopoietic contexts, including physical co-operativity with HP1a and LSD1. Here we discuss new evidence for a BAP1-independent function of ASXL1 in regulating histone H3 lysine 27 methylation through interactions with the Polycomb-repressive complex 2 (PRC2). BAP1, a nuclear-localized deubiquitinase, has been shown to interact with a number of proteins, including ASXL1 and/or ASXL2, but the functional importance of this interaction has remained elusive. Here, we highlight recent work revealing the critical function of BAP1 in restricting myelopoiesis and in regulating hematopoietic stem cell function. These data provide evidence that BAP1 and ASXL1 function as a novel class of tumor suppressors in myeloid malignancies. BAP1 functions through effects on stability of host cell factor-1, and O-GlcNAcylation, and ASXL1 impacts histone post-translational modifications through interaction with PRC2. Future studies investigating the mechanism of transformation by loss of BAP1 and ASXL1 may result in new therapeutic approaches to treat hematological malignancies.
INTRODUCTION
The dysregulation of transcription factors has long been suspected to have an important role in myeloid transformation based on the identification of recurrent translocations involving transcription factors in myeloid malignant disorders. More recently, recurrent somatic mutations in transcription factors as well as epigenetic regulators of transcription have been identified in a large proportion of patients with cytogenetically normal myelodysplastic syndrome (MDS) and acute myeloid leukemia. In addition to continuing mutation discovery efforts in these disorders, a great deal of effort is also being placed in functionally understanding how these mutations contribute to myeloid transformation, and identifying the critical target genes and downstream transcriptional programs affected by these alterations. Here we discuss two recent studies that identify novel functions for BAP1 1 and ASXL1 (additional sex combs-like) 2 in myeloid transformation. BAP1 and the ASXL family of proteins have been shown to interact in metazoan cells using multiple proteomic approaches. 1, 3, 4 Although little was previously known about the function or importance of these proteins, recent reports from cancer genome sequencing studies, biochemical characterization and novel mouse models have identified overlapping as well as independent roles for these two genes in hematopoiesis and myeloid malignancies.
ASXL1: A POLYCOMB GROUP PROTEIN FREQUENTLY MUTATED IN MYELOID MALIGNANCIES
ASXL1, ASXL2 and ASXL3 are the human homologs of Drosophila additional sex combs (Asx). Asx deletion results in a homeotic phenotype characteristic of both Polycomb group (PcG; repressive complex) and Trithorax group (activating) gene deletions, 5 which led to the hypothesis that Asx has dual functions in silencing and activation of homeotic gene expression. In addition, functional studies in Drosophila suggest that Asx encodes a chromatinassociated protein with similarities to PcG proteins (5) . A series of in vitro studies in non-hematopoietic cells have suggested a variety of functions for ASXL1, including physical co-operativity with HP1a and LSD1 to repress retinoic acid-receptor activity and interaction with peroxisome proliferator-activated receptor-g to suppress lipogenesis. [6] [7] [8] All three ASXL family members are characterized by an aminoterminal homology domain and a C-terminal plant homeodomain. 8, 9 Recent bioinformatics analysis of the conserved domains of mammalian ASXL proteins has suggested that the N-terminal domain of ASXL1 (amino acids 10-100) might represent a unique DNA binding motif, termed a HARE-HTH domain (HB1, ASXL1, restriction endonuclease helix-turn helix domain). 10 On the basis of comparative analysis with other plant homeodomaincontaining proteins, the plant homeodomain of ASXL proteins appears unique and has been predicted to potentially recognize internal methylated lysines on histone H3 tails as opposed to lysines on the N-terminal tail of histone H3. Further functional investigation will be needed to understand the role of these domains of the ASXL family members.
Interestingly, frequent mutations in ASXL1 have recently been identified in the entire spectrum of myeloid malignancies [11] [12] [13] [14] [15] [16] ( Table 1) . In fact, mutations in ASXL1 appear to be novel biomarkers of adverse overall survival in patients with MDS and SPOTLIGHT 1 acute myeloid leukemia, [11] [12] [13] [14] [15] [16] independent from other clinically utilized prognosticators.
ASXL1 REGULATES HISTONE H3 LYSINE 27 METHYLATION
To investigate the functional implication of ASXL1 mutations, we recently characterized the effects of these mutations on ASXL1 protein expression in vitro.
2 Mutations in ASXL1, although present throughout the coding region, occur most frequently as nonsense as well as frameshift mutations in the 5 0 -end of the last exon, suggesting that these mutations might result in a truncated protein product lacking the plant homeodomain. 12, 17 However, characterization of ASXL1 protein expression in cell types bearing endogenous expression of these mutant forms of ASXL1 revealed downregulation in ASXL1 protein expression with no truncated protein product in these cell lines. 2 Indeed, leukemia-associated mutations in ASXL1 appear to result in reduced stability of the mutant forms of ASXL1 relative to wild type. The mutant forms of ASXL1 undergo more rapid degradation following cycloheximide exposure in cells. 2 Given that Asx mutations in Drosophila appear to affect both PcG and Trithorax group function, we characterized the effects of ASXL1 loss on canonical marks of the PcG and Trithorax group gene function (histone H3 lysine 27 trimethyl (H3K27me3) and histone H3 lysine 4 trimethyl (H3K4me3), respectively). Western blots of purified histones from isogenic myeloid hematopoietic cells with and without ASXL1, as well as chromatin immunoprecipitation sequencing revealed a striking global loss of H3K27me3 upon ASXL1 loss. Moreover, this loss of H3K27me3 was seen despite no change in the levels of the core Polycombrepressive complex 2 (PRC2) members (EZH2, EED and SUZ12) responsible for H3K27 methylation. 2 Interestingly, chromatin immunoprecipitation for EZH2 in the presence and absence of ASXL1 suggested that ASXL1 is important for recruitment and/or stabilization of the PRC2 complex at key locations in the genome. In accordance with this, ASXL1 was also found to physically interact with core PRC2 members. Conversely, re-expression of ASXL1 in myeloid leukemia cells with complete loss of ASXL1 due to homozygous mutation revealed an increase in H3K27me1/2/3 levels by chromatin immunoprecipitation and mass-spectrometric analysis of histones. Though the BAP1-ASXL1 Polycomb-repressive deubiquitinase complex in Drosophila melanogaster has been suggested to be a H2A deubiquitinase (described below), 18 the effects of ASXL1 loss on histone H2A lysine 119 ubiquitin (H2AK119Ub) levels were minimal compared with the effects on H3K27me3. 2 Given the epigenomic and physical interaction between ASXL1-and the EZH2-containing PRC2 complex members, it will be important to identify whether ASXL1 This table reports only somatic mutations in BAP1, ASXL1 and ASXL2. Copy-number alterations and changes in expression of each of these genes have been reported, but have not been systematically performed or reported across studies or tumor types. Rare somatic ASXL3 mutations have been described in ovarian and pancreatic adenocarcinoma, but recurrent mutations (for example, with a frequency of 45%) in ASXL3 have not been identified in any single human disorder.
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New factors in myelopoiesis, cancer and epigenetics O Abdel-Wahab and A Dey similarly interacts with EZH1, the homolog of EZH2 with known ability to methylate H3K27 in vitro and in vivo. 19, 20 To identify potential target genes affected by ASXL1 loss, gene expression data from isogenic cells with ASXL1 knockdown or control was intersected with H3K27me3 and H3K4me3 chromatin immunoprecipitation sequencing data from the same cell type. This analysis revealed that the HOXA cluster of genes had a distinct H3K27me3 loss and a concomitant upregulation in expression upon ASXL1 loss. Despite the striking effects of BAP1 loss on myeloproliferation (described below), there appears to be minimal effect of conditional deletion of Bap1 in mice or knockdown of BAP1 in vitro on upregulation of HOXA gene members, 1,2 suggesting some divergence in the function of BAP1 and ASXL1.
Although upregulation of HOXA gene members was prominent from in vitro analyses following ASXL1 knockdown in primary hematopoietic cell types and transformed myeloid leukemia cell lines, prior work characterizing a mouse model with constitutive loss of Asxl1 revealed no overt hematopoietic malignancy upon Asxl1 loss. 9 Analysis of the effects of Asxl1 loss from this previous mouse model was possibly obscured due to high perinatal lethality seen in mice with germline loss of Asxl1. Moreover, loss of Asxl1 using in vivo RNA-interference methodology in the presence of oncogenic forms of NRasG12D revealed a clear collaborative effect of Asxl1 loss in promoting myeloproliferation induced by NRasG12D, and this was associated with upregulation of 5 0 -HOXA genes. 2 Currently, there is no published description of the effects of conditional deletion of Asxl1 from the hematopoietic compartment and further work to characterize this will be important to clarify the in vivo effects of Asxl1 on hematopoiesis.
BAP1: A DEUBIQUITINATING ENZYME MUTATED IN HUMAN MALIGNANCY
BAP1 is a nuclear-localized deubiquitinating enzyme and a member of the ubiquitin C-terminal hydrolase family. It was the first nuclear-localized ubiquitin C-terminal hydrolase enzyme to be identified and was originally discovered as a protein interacting with the RING finger domain of BRCA1.
21 BAP1 was shown to enhance the growth-suppressive effect of BRCA1 and, thus, it was hypothesized that BAP1 may deubiquitinate BRCA1. 21 It was subsequently found that BAP1 does not deubiquitinate BRCA1, and BAP1 can inhibit malignant cell proliferation in a BRCA1-independent manner, suggesting that BAP1 likely functions in processes not related to BRCA1. 22 Although the function of BAP1 remained elusive for some time, several pieces of evidence suggested that BAP1 was a likely tumor suppressor shortly after its discovery. First, the BAP1 locus (3p21.3) undergoes frequent copy-number loss and loss-of-heterozygosity in several cancers. For instance, deletions in 3p are seen in the vast majority of small-cell and non-small cell lung cancer cell lines, 21 as well as renal cell carcinoma tumors. 23 Second, BAP1 overexpression was shown to suppress tumorigenicity of many transformed cell types that have homozygous loss of the locus containing BAP1. 22 In line with this, loss-of-function BAP1 mutations have recently been identified in a diverse array of solid tumor types [24] [25] [26] [27] [28] [29] [30] (Table 1) . This includes frequent somatic mutations in malignant pleural mesothelioma, 26 uveal melanoma 24 and clear cell renal carcinoma. 29, 30 The BAP1 mutations have been reported to occur as missense, nonsense and out-of-frame insertions/deletions throughout the open-reading frame. Furthermore, germline BAP1 mutations have been prominently described in patients with uveal melanoma, 25, 28 mesothelioma, 25, 28 as well as patients with both uveal melanoma and mesothelioma. 25, 27, 28 Given the rarity of spontaneous cases of either uveal melanoma or mesothelioma, it appears that germline mutations in BAP1 define a new hereditary cancer syndrome characterized by uveal melanoma and mesothelioma, and possibly other malignancies.
In addition to the above, we recently identified a somatic heterozygous BAP1 mutation in a patient with de novo MDS and deletion of 20q as the sole additional somatic abnormality. 1 Although only a small cohort of patients (32 total) was sequenced for BAP1 mutations, we identified more frequent downregulation in expression of BAP1 in CD34 þ cells from patients with de novo MDS compared with age-matched counterparts. 31 Given the striking phenotype resulting from systemic deletion of Bap1 in mice (described below), further work to identify the frequency of somatic BAP1 mutations in myeloid malignancies, clinical correlates of BAP1 mutations and downregulated expression, and mutations co-occurring with alterations in BAP1 would aid in our understanding of the role of BAP1 in the pathogenesis of myeloid malignancies.
A NOVEL ROLE FOR BAP1 IN HEMATOPOIESIS
To investigate the biological function of Bap1, we recently created a murine model with deletion of Bap1. 1 Given that constitutive loss of Bap1 resulted in embryonic lethality, we generated mice with inducible deletion of Bap1 using creERT2 technology. Strikingly, within 4 weeks following tamoxifen injection to induce deletion of Bap1, 100% of Bap1 knockout (KO) mice developed splenomegaly due to extramedullary hematopoiesis. The peripheral blood of these mice was characterized by severe, progressive monocytosis, neutrophilia, anemia and thrombocytopenia. Morphological examination revealed dysplastic features in the myeloid cells. The proliferative features combined with features of ineffective hematopoiesis following Bap1 deletion most resembled an MDS/Myeloproliferative neoplasm overlap disorder such as human chronic myelomonocytic leukemia. Deletion of only a single copy of Bap1 resulted in a significantly milder phenotype than deletion of both copies of Bap1.
At the hematopoietic stem cell level, systemic Bap1 deletion resulted in an increase in the number of cells containing the hematopoietic stem cells (the lineage-negative, Sca-1 þ , c-KIT þ (LSK) cells and lineage-negative, Sca-1 À , c-KIT þ (myeloid progenitor) cells) in the bone marrow. Intriguingly, the Bap1-deficient bone marrow progenitors exhibited decreased selfrenewal as assayed by in vitro colony-forming assays and competitive transplantation assays using whole bone marrow mononuclear cells depleted of Bap1 before transplantation. 1 One possible explanation for this apparent conundrum is that Bap1 loss effects hematopoietic stem cell engraftment and/or homing, although further work will be needed to ascertain this. Finally, Bap1 deficiency resulted in a chronic myelomonocytic leukemialike phenotype in a cell-autonomous manner, as Bap1 deletion after reconstitution of lethally irradiated recipient mice resulted in the same features as the primary Bap1 conditional KO mice.
THE BAP1-ASXL CONNECTION
As a member of the ubiquitin C-terminal hydrolase family, BAP1 possesses a conserved catalytic domain. 21 In addition, BAP1 possesses a large C-terminal domain not present in other ubiquitin C-terminal hydrolase members, which was previously predicted to have an important role in regulating and coordinating its deubiquitinating enzyme activity through selective association with potential substrates or regulatory components. In order to identify BAP1 interacting proteins, we utilized a novel methodology of immunoprecipitation and mass-spectrometric detection coupled with in vivo stable isotope labeling of amino acids. 1 We created a Bap1.3 Â Flag knock-in mouse and then performed an immunoprecipitation for FLAG epitope in lysates from spleen and brain of knock-in mice and littermate wild-type mice fed a diet of 13 Recent studies from D. melanogaster suggested that BAP1 and ASXL1 associate to a new PcG protein complex(Polycombrepressive deubiquitinase complex), which serves to remove mono-ubiquitin from H2AK119. 18 This interaction is critical for the enzymatic activity of BAP1. Moreover, there appears to be reduced co-immunoprecipitation of BAP1 with ASXL1 in cells bearing mutant forms of ASXL1.
2 It is worth noting that this could be due to the decreased stability of the ASXL1 mutants. Although the intersection of ASXL1 and BAP1 in H2AUb deubiquitination and thereby in the regulation of myelopoiesis seems attractive, a number of findings suggest that BAP1 and ASXL1 may function independently. First, although germline 33 and somatic mutations in ASXL1
12,17 as well as somatic mutations in ASXL2 34 have now been described in a number of disorders, there appears to be very little overlap in the disorders where BAP1 and ASXL1 members are mutated (Table 1 ). For instance, as mentioned earlier BAP1 appears to be mutated most commonly in mesothelioma, uveal melanoma and clear cell renal cell carcinoma, whereas ASXL1 is commonly mutated in myeloid malignancies and ASXL2 is mutated in metastatic prostate carcinoma (Table 1) . Moreover, germline mutations in BAP1 are associated with the hereditary cases of uveal melanoma and/or mesothelioma, whereas germline mutations in ASXL1 are associated with the severe developmental disorder Bohring-Opitz Syndrome. 33 Finally, a clear relationship between BAP1 or ASXL1 mutation/loss and global H2AK119Ub levels in mammalian cells has not been readily apparent.
1,2,30 These differences may, however, be contextdependent and warrant further investigation. At the same time, we cannot exclude the possibility that the true incidence of BAP1 mutations/downregulation in hematopoietic malignancies has not been fully appreciated, given the lack of published candidate gene-sequencing studies of BAP1 in patients with hematopoietic disorders.
BAP1 REGULATES HCF-1 AND OGT STABILITY
Previous work by Misaghi et al., 35 Machida et al. 3 and Sowa et al. 4 identified that BAP1 interacts with HCF-1, a pleiotropic transcriptional regulator that has been extensively studied as a regulator of cell proliferation (reviewed in Eletr and Wilkinson 36 ). BAP1 deubiquitylates HCF-1 to prevent its proteasomal degradation 3, 4, 35 (Figure 1 ). Confirming the functional interaction of BAP1 with HCF-1, we found that Bap1 KO mouse cells exhibit strikingly decreased HCF-1 levels. 1 Moreover, Bap1 KO cells showed a decrease in OGT levels and O-GlcNAc (O-linked b-D-Nacetylglucosamine) levels, 1 suggesting that Bap1 regulates the stability of OGT and HCF-1. This data further suggests that BAP1 HCF-1, ASXL1 and/or ASXL2, and OGT might form a BAP1 core complex, and that ASXL1 may also serve in BAP1-independent complexes (Figure 1) .
On the basis of the discovery of downregulation of BAP1 expression in MDS patients, the discovery of an MDS patient with a somatic BAP1 mutation and the murine model clearly linking Bap1 loss to a chronic myelomonocytic leukemia-like phenotype, it will be fascinating to investigate the role of HCF-1 and/or OGT in hematopoiesis and myeloid malignancies. HCF-1 is thought to promote cell cycle progression at the G1/S boundary by recruiting H3K4 methyltransferases to E2F transcription factors, to transcribe genes needed to enter S-phase. [37] [38] [39] Effect of Bap1 loss on quiescence, proliferation and cycling of hematopoietic stem cells would be enlightening.
OGT is a single, highly conserved enzyme, which catalyzes the addition of the sugar O-GlcNAc to proteins. 40 O-GlcNAcylation is a nutrient-sensitive sugar modification that participates in a bewildering array of cellular processes, and is thought to link New factors in myelopoiesis, cancer and epigenetics O Abdel-Wahab and A Dey nutrient availability to chromatin structure. How exactly BAP1 loss may affect the pattern of O-GlcNAcylated proteins and the ensuing effects on chromatin structure remain to be identified.
SPOTLIGHT
Although Asx in D. melanogaster is required for the enzymatic activity of BAP1 (Calypso), 18 it is not clear if loss of ASXL proteins affects the levels of HCF-1 or OGT in the manner that BAP1 loss affects the abundance of these proteins. One possibility is that ASXL1 and ASXL2 may have redundant functions in the interactions with BAP1, thus limiting the deleterious effects of either ASXL1 or ASXL2 alone. Interestingly, a prior gene trap KO model of Asxl2 revealed global effects of downregulated H3K27 methylation as has been recently identified with Asxl1. 41 Further work to understand the effects of Asxl2 loss using conditional deletion of Asxl2 may be fruitful given the recently identified presence of ASXL2 mutations in human malignancies (Table 1) .
CONCLUDING REMARKS
Mutations in BAP1 and ASXL gene members are present in a diverse number of human disorders highlighting the importance of these genes in a number of biological processes. Investigations into the function of BAP1 and ASXL1 in the context of hematopoietic cells have uncovered a number of novel insights, including the role of deubiquitylation of nuclear proteins in myeloid malignancies, a possible role for HCF-1 and OGT in myeloid transformation, and new insights into PRC2-mediated gene repression in mammals. BAP1 and ASXL1 appear to be involved in a large number of protein-protein interactions. Future work dissecting the overlapping and independent complexes where BAP1 and ASXL1 are involved will undoubtedly shed light on the role of these proteins in malignancies. Also, given the frequency of BAP1 mutations in many epithelial malignancies, it will be interesting to ascertain the effect of Bap1 loss on nonhematopoietic tissues.
On the basis of the frequent mutations of ASXL1 in myeloid malignancies and the striking chronic myelomonocytic leukemialike phenotype observed upon BAP1 deletion, it is tempting to speculate that the BAP1-ASXL axis could be a central factor in myelopoiesis. The importance and complexity of this interaction warrants further investigation. Moving ahead, it will be important to elucidate the structural basis of the BAP1-ASXL interaction and investigate the molecular mechanism by which they normally restrict myelopoiesis. Finally, further investigation of the effects of ASXL1 and BAP1 mutations in hematopoiesis could result in novel therapeutic insights, as these proteins are critical for several enzymatic functions that might be therapeutically intervenable. Specific questions to be explored in the near future include characterizing the function of conserved domains in the ASXL proteins, identifying the effect (if any) of ASXL1 loss on HCF-1 and OGT levels, determining the biological implication of ASXL1 loss using conditional gene-targeting means, understanding the role of HCF-1 and OGT on hematopoiesis and myeloid malignancies, characterizing the incidence of BAP1 mutation and/or downregulation in hematopoietic malignancies, and determining whether ASXL2 has a redundant/overlapping function with ASXL1. These are all topics of intense investigation by various researchers and promise exciting discoveries in the years to come.
